The oral anti-diabetes drug market is in for a major shake-up as Merck, Sharp & Dohme’s (MSD’s) Januvia is expected to go off-patent this month. According to market research firm AIOCD, at least 50 Indian drug makers are jumping into the fray with around 100 generic versions of the popular anti-diabetes medication, leading to a likely price war.
Analysts expect prices to drop by 60% with the entry of generics, and intensify competition for vildagliptin and teneligliptin, two molecules of the same class that went off-patent in 2019 and 2015, respectively.
Hi, this is a comment.
To get started with moderating, editing, and deleting comments, please visit the Comments screen in the dashboard.
Commenter avatars come from Gravatar.